Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.23.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 1,267,453 $ 1,169,254
Selling, general and administrative 1,154,916 1,810,030
Total operating expenses 2,422,369 2,979,284
Loss from operations [1] (2,422,369) (2,979,284)
Other income (expense):    
Interest expense, net (263,195) (3,662)
Gain on amendment of contracts 1,226,432 0
Other, net (17,198) (4,299)
Total other income (expense), net 946,039 (7,961)
Net loss (1,476,330) (2,987,245)
Loss attributable to noncontrolling interest 1 3
Loss attributable to common stockholders $ (1,476,329) $ (2,987,242)
Loss attributable to common stockholders per common share (basic and diluted) (in dollars per share) $ (0.05) $ (0.10)
Weighted average shares outstanding (in shares) 32,654,012 30,207,746
[1] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.